Improved vaccines and methods for using the same

This invention represents significant advancement in immunological protection, offering novel approaches to preventing and treating infectious diseases and cancer through improved vaccine technologies and methodologies.

The Problem

Infectious diseases and various forms of cancer represent major global health challenges. Current vaccine approaches often struggle with viral mutation and diversity, requiring continuous updates and modifications. Additionally, some diseases lack effective preventive vaccines, leaving vulnerable populations at risk of serious complications or mortality. Healthcare systems worldwide face the challenge of developing vaccines that can protect against multiple disease variants while maintaining high efficacy across different populations.

What This Invention Does

This patent discloses improved immunogenic formulations that address key limitations in existing vaccine approaches. The invention provides novel nucleic acid constructs and protein sequences optimized for generating strong immune responses. By utilizing consensus and ancestral sequence strategies, the immunogens are designed to provide broader protection against diverse viral strains and disease variants.

Key Features

Multi-Strain Coverage. The immunogens target multiple disease subtypes including Subtypes A, B, C, and D, enabling protection against diverse viral variants that might emerge in different geographic regions or populations.

Optimized Expression Systems. The constructs incorporate codon optimization and RNA optimization techniques to maximize protein expression levels and enhance the immunogenicity of the vaccines.

Combination Therapy Potential. The invention enables use of multiple immunogens in combination, such as pairing hTERT targeting with HPV or HCV immunogens for enhanced therapeutic outcomes in cancer and viral disease treatment.

Flexible Delivery Methods. The technology supports multiple vaccine formats including pharmaceutical compositions, recombinant vaccines, and live attenuated pathogen systems.

Who Is Behind It?

The Trustees of the University of Pennsylvania, a leading research institution in the United States, developed this invention with David B. Weiner, Jian Yan, and Dominick Laddy as inventors. This application is a divisional of multiple predecessor applications, with priority tracing back to July 2006, demonstrating the long-term development and refinement of this vaccine technology. The work builds on decades of immunological research at one of America’s most prestigious academic medical centers.

Why It Matters

This invention has profound implications for public health and vaccine development globally. By providing tools to overcome viral diversity and create more effective vaccines, the technology could enhance protection against diseases that kill thousands annually. The multi-disease application of the underlying technology means a single platform can potentially be adapted for HIV, HPV, HCV, influenza, and cancer immunotherapy, accelerating the pace of vaccine development.

The patent falls within IPC classifications C07H 21/04 (nucleic acids) and C07K 14/00 (proteins), indicating its fundamental importance to biotechnology. As healthcare systems and pharmaceutical companies increasingly seek to expand vaccine portfolios and improve efficacy, technologies offering broader strain coverage and optimized expression become increasingly valuable.

---

AU 2026201472 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

DNA and nucleic acid vaccines deliver genetic instructions encoding a target antigen directly into cells, prompting an immune response without using live pathogens. Codon optimisation maximises protein expression in human cells, improving immunogenicity. These platforms are inherently flexible – the same delivery system can be adapted against HIV, HPV, cancer antigens, and emerging pathogens, making nucleic acid vaccine technology one of the most versatile tools in modern vaccinology.